Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Safety of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease Treated With Immunomodulatory or Biological Drugs

X
Trial Profile

Effectiveness and Safety of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease Treated With Immunomodulatory or Biological Drugs

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Acronyms ESCAPE-IBD
  • Most Recent Events

    • 01 Feb 2023 Results of serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls, published in the Digestive and Liver Disease
    • 11 Oct 2022 Results (n=809) assessing safety of Covid-19 Vaccine in Patients with Inflammatory Bowel Disease treated with immunomodulatory or bio-logical drugs, presented at the 30th United European Gastroenterology Week.
    • 11 Oct 2022 Results assessing effectiveness and safety of COVID-19 vaccine in Patients with inflammatory Bowel Disease (IBD) Treated with Immuno-modulatory or Biological Drugs presented at the 30th United European Gastroenterology Week
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top